Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

629
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
629
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Bone Disorders01:29

Bone Disorders

7.5K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
7.5K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

4.7K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.7K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

936
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
936
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osteoporosis treatment adherence trajectories, comedication patterns, and romosozumab persistence among early users: A data-driven analysis.

Bone·2026
Same author

Consensus statement on the application of artificial intelligence in osteoporosis screening and management: perspectives from the Asia-Pacific region.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Health literacy and happiness: A community-based study.

Social indicators research·2026
Same author

Glucocorticoid-induced osteoporosis: novel concepts and clinical implications.

The lancet. Diabetes & endocrinology·2025
Same author

Socioeconomic vulnerability and osteoporosis treatment disparities during COVID-19 lockdown among U.S. medicare enrollees who initiated romosozumab.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval?

The Journal of rheumatology·2025

Related Experiment Video

Updated: Mar 29, 2026

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
05:55

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head

Published on: September 27, 2024

1.1K

Glucocorticoid-induced Osteoporosis.

Xena Whittier1, Kenneth G Saag2

  • 1Division of Clinical Immunology and Rheumatology, 851 Faculty Office Tower, 510 20th Street South, Birmingham, AL 35294, USA.

Rheumatic Diseases Clinics of North America
|November 28, 2015
PubMed
Summary

Glucocorticoid-induced osteoporosis (GIOP) is a serious side effect of steroid medication. Early intervention and lifestyle changes can reduce fracture risk for long-term users.

Keywords:
Fracture riskGlucocorticoidsOsteoporosisPrevention

More Related Videos

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments
06:16

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments

Published on: May 9, 2019

8.1K
Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.5K

Related Experiment Videos

Last Updated: Mar 29, 2026

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
05:55

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head

Published on: September 27, 2024

1.1K
Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments
06:16

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments

Published on: May 9, 2019

8.1K
Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.5K

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Glucocorticoid medications are widely used but can cause significant bone loss.
  • Glucocorticoid-induced osteoporosis (GIOP) is a common adverse effect, increasing fracture risk.
  • Understanding GIOP is crucial for managing patients on long-term glucocorticoid therapy.

Purpose of the Study:

  • To review the pathophysiology of GIOP.
  • To discuss the epidemiology and risk factors associated with GIOP.
  • To outline effective treatment and prevention strategies for GIOP.

Main Methods:

  • Literature review of GIOP pathophysiology.
  • Analysis of epidemiologic data on GIOP prevalence.
  • Synthesis of current treatment guidelines and lifestyle recommendations.

Main Results:

  • Glucocorticoids disrupt bone remodeling, leading to decreased bone mineral density.
  • Long-term glucocorticoid users face a substantially increased risk of fractures.
  • Early detection and intervention are key to mitigating GIOP complications.

Conclusions:

  • GIOP management requires a multifaceted approach including pharmacologic treatment and lifestyle adjustments.
  • Patient education on fracture risk reduction is essential.
  • Prompt intervention can significantly improve outcomes for patients using glucocorticoids.